EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases

Asuka Shibamiya, Chikako Ohwada, Yuka Tsutsui, Akane Tanaka, Reiko Watanabe, Taro Akatsuka, Toshihisa Hamada, Makoto Sugaya, Yuichiro Hayashi, Takayuki Shiomi, Chiaki Nakaseko

Journal of Clinical and Experimental Hematopathology · 2026

DOI: 10.3960/jslrt.25056 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2026. Verfasst von Asuka Shibamiya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan. Hauptthemen laut MEDLINE: Blastic Plasmacytoid Dendritic Cell Neoplasm, Azacitidine, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with no established standard treatment. Recently, the combination of venetoclax (VEN) and azacitidine (Aza) has shown promising efficacy in elderly or unfit patients; however, clinical data in Japanese patients remain limited. We report two Japanese cases with BPDCN that responded favorably to VEN plus Aza therapy. The first case involved a 50-year-old man who relapsed shortly after Hyper-CVAD/MA therapy with leukemic transformation. Despite requiring dose reductions due to prolonged cytopenia and infections, he achieved a complete response after eight cycles of VEN plus Aza. The second case was an 81-year-old man with widespread skin and bone marrow lesions. He showed a marked clinical response after only 7 days of treatment, although therapy was discontinued due to COVID-19 infection. Both cases demonstrate that VEN plus Aza therapy can induce rapid and clinically meaningful responses even in short or attenuated regimens in patients with refractory or elderly BPDCN. However, cytopenias and infections are significant limitations, warranting that individualized dosing may be necessary depending on patient characteristics, including ethnicity and body size. Our findings support the consideration of VEN plus Aza as a feasible therapeutic option for patients with BPDCN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blastic Plasmacytoid Dendritic Cell NeoplasmAzacitidineSulfonamidesBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAged, 80 and overMiddle AgedTreatment OutcomeJapanEast Asian People

Stichwörter der Autor:innen

azacitidineblastic plasmacytoid dendritic cell neoplasmvenetoclax

Substanzen

AzacitidineSulfonamidesvenetoclaxBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan.
  • Department of Dermatology, International University of Health and Welfare Narita Hospital, Narita, Japan.
  • Department of Anatomic Pathology, International University of Health and Welfare Narita Hospital, Narita, Japan.

Zitieren

APA

Shibamiya, A., Ohwada, C., Tsutsui, Y., Tanaka, A., Watanabe, R., Akatsuka, T., Hamada, T., Sugaya, M., Hayashi, Y., Shiomi, T., & Nakaseko, C. (2026). Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.25056

Vancouver

Shibamiya A, Ohwada C, Tsutsui Y, Tanaka A, Watanabe R, Akatsuka T, et al. Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases. Journal of Clinical and Experimental Hematopathology. 2026. doi:10.3960/jslrt.25056

BibTeX
@article{Shibamiya2026,
  author = {Shibamiya, Asuka and Ohwada, Chikako and Tsutsui, Yuka and Tanaka, Akane and Watanabe, Reiko and Akatsuka, Taro and Hamada, Toshihisa and Sugaya, Makoto and Hayashi, Yuichiro and Shiomi, Takayuki and Nakaseko, Chiaki},
  title = {Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases},
  journal = {Journal of Clinical and Experimental Hematopathology},
  year = {2026},
  doi = {10.3960/jslrt.25056}
}
Kostenlos starten →